SEC Form 10-Q Summary
Filing identity: The provided filing is for Zeta Acquisition Corp. II, not Whitehawk Therapeutics, Inc. It covers the quarterly period ended June 30, 2014, was filed August 14, 2014, and presents unaudited financial statements.
Business Context and Reporting Period
Zeta Acquisition Corp. II was a Delaware development-stage, blank-check and shell company formed to identify and complete a business combination. It had no operating business, generated no revenue since inception, and had not identified or negotiated with a target company as of the filing date. The company had 5,000,000 common shares outstanding.
Financial Position and Results
| Metric | June 30, 2014 / Q2 2014 | Comparable Period or December 31, 2013 |
|---|---|---|
| Revenue | $0 | $0 |
| Three-month net loss | $6,952 | $6,749 loss in Q2 2013 |
| Six-month net loss | $12,718 | $12,812 loss in six months ended June 30, 2013 |
| Operating expenses, six months | $9,445 | $10,262 |
| Interest expense, six months | $3,273 | $2,550 |
| Cash and cash equivalents | $4,568 | $6,283 at December 31, 2013 |
| Total current liabilities | $141,528 | $133,025 at December 31, 2013 |
| Stockholders’ deficit | $136,960 | $124,242 at December 31, 2013 |
| Notes payable to stockholders | $110,000 | $110,000 at December 31, 2013 |
Six-month operating cash outflow was $1,715, compared with $11,187 in the prior-year period. There was no investing cash flow and no financing cash flow during the first six months of 2014. Accrued and unpaid interest was $20,448 at June 30, 2014. The company reported a cumulative inception-to-date net loss of $186,960 and cumulative net cash used in operating activities of $155,432.
Profit margins are not meaningful because the company had no revenue or operating business.
Material Changes Versus the Prior Comparable Period
- Q2 net loss increased modestly to $6,952 from $6,749, primarily because of higher interest expense.
- Six-month net loss decreased slightly to $12,718 from $12,812, reflecting lower general and administrative expense, partly offset by higher interest expense.
- Cash declined by $1,715 from December 31, 2013, while current liabilities increased by $8,503.
- Accounts payable increased to $8,155 from $350, and accrued interest increased to $20,448 from $17,175.
- Prepaid expenses declined from $2,500 to zero.
- Unlike the prior-year six-month period, the company received no stockholder-loan financing in the first six months of 2014.
Guidance, Outlook, Risks and Unusual Items
Management planned to continue searching for a suitable acquisition candidate and expected to incur costs for SEC reporting and acquisition-related investigations. The company stated that it could fund near-term costs through available cash, deferred service-provider fees, and additional stockholder, management or investor financing, but provided no assurance that such funding would be available.
Management identified substantial going-concern risk. The company had only $4,568 of cash against $141,528 of current liabilities, depended on related-party financing, had no revenues, and could not assure that it would meet cash requirements for the next twelve months. Continuation depended on obtaining financing, generating profitable operations, and completing a suitable business combination.
The $110,000 of stockholder notes are unsecured, bear 6% interest, and are due on demand. The company also had approximately $63,600 of deferred tax assets fully offset by a valuation allowance. It reported no material legal proceedings, no off-balance-sheet arrangements, no unregistered equity sales, and no defaults upon senior securities.
The company elected the extended transition period for adopting certain accounting standards under the JOBS Act. It had not early adopted ASU 2014-10, which eliminates development-stage-entity reporting requirements.
Management concluded that disclosure controls and procedures were effective as of June 30, 2014, with no material changes in internal control during the quarter.
Investor Verification Items
- Confirm the issuer identity: the source filing is for Zeta Acquisition Corp. II, whereas the request identifies Whitehawk Therapeutics, Inc.
- Verify the company’s ability to obtain additional financing and remain a going concern.
- Review the terms, holders and demand status of the $110,000 stockholder notes and the $20,448 accrued interest.
- Assess whether a business combination has been identified or subsequently completed; none had been identified as of the filing.
- Reconcile the very limited cash balance with current liabilities and expected reporting and transaction expenses.
- Consider the risks of investing in a shell company with no revenue, no operating history and potentially limited diversification after any future combination.